Key result
Dapagliflozin transfers into breast milk at ~8% relative infant dose, below acceptable exposure limits.
Why the study?
Dapagliflozin prevents the development and slows the progression of heart failure, but published data demonstrating the safety of SGLT2 inhibitors in postpartum lactating individuals were limited.
What is the breast milk transfer and relative infant dose of dapagliflozin in postpartum lactating women?
What is the breast milk transfer and relative infant dose of dapagliflozin in postpartum lactating women?
Answers are grounded in this paper and cite their sources.
This first-in-human lactation pharmacokinetic study shows that dapagliflozin transfers into breast milk at low levels (mean RID 7.73%, below the 10% threshold of concern), providing preliminary data to inform future research and shared decision-making for breastfeeding patients with heart failure.
Background: Dapagliflozin (DAPA), a sodium-glucose co-transporter inhibitor (SGLT2i), has been shown to prevent the development of heart failure and slow the progression of pre-existing heart failure; however, there are limited data published to demonstrate the safety of postpartum lactating individuals taking SGLT2is. Methods: Lactating patients received two oral doses of 10 mg DAPA over a 48-h period. Breast milk and plasma were collected 2 h after the second dose. Samples were processed via liquid chromatography mass spectrometry (LCMS) analysis. Breast milk concentrations of DAPA were divided by plasma concentrations of DAPA (in ng/mL). The absolute (AID; i.e., daily infant dose) and relative infant doses (RID) were performed. An RID of 10% was considered the limit of acceptable exposure. Results: mg/day and the mean RID was 7.73 ± 3.9%. Conclusions: This study demonstrates that human breast milk collected at peak anticipated maternal concentrations of DAPA has a mean RID below 10%. This is the first report of human transfer levels for DAPA, generating preliminary lactation-specific pharmacokinetic data that are essential to support evidence-based treatment of breastfeeding individuals and reduce disparities in their representation within cardiovascular therapeutic research.
No takes yet. Share an insight, caveat, or question.
Bartell et al. (2026) studied Postpartum lactation (pharmacokinetic assessment for heart failure management) (n=4). Dapagliflozin was evaluated on Relative infant dose (RID) of dapagliflozin in breast milk at peak maternal plasma concentration (2 hours after second dose). Dapagliflozin resulted in a mean relative infant dose of 7.73 ± 3.9% in human breast milk, remaining below the 10% clinical limit of acceptable exposure.
Synapse has enriched 10 related papers. Consider them for comparative context: